StockData
Enovis CORP logo

Enovis CORP (ENOV) company profile

ENOVNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jul 3, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3066% below fair value
$27.10−0.12 (-0.44%)

Close on Nov 18, 2026Market cap $1.56BP/E –Yield –

About Enovis

Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842

Enovis Corporation is a medical technology company that develops, manufactures, and distributes medical devices across the care continuum, from injury prevention to joint replacement and post-operative rehabilitation. The company operates through two segments: Prevention & Recovery, and Reconstructive. The Prevention & Recovery segment provides orthopedic braces, temperature therapies, bone growth stimulators, compression garments, and pain management equipment. The Reconstructive segment supplies surgical implants, instrumentation, and digital planning technologies for joint replacement and limb reconstruction. Enovis serves orthopedic specialists, surgeons, physical therapists, healthcare systems, and retail consumers.

The company conducts business internationally, with primary geographic markets in the United States and Europe, alongside operations in the Asia-Pacific region. Products are distributed globally through direct sales personnel and independent distributor networks. Enovis also sources raw materials and component parts from diverse global suppliers. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Enovis's latest annual report, written by StockData.

Company profile

Company

Legal name
Enovis CORP
Founded
1998
Headquarters
Lewisville, TX
Address
2900 Lake Vista Drive, Suite 200 75067
Phone
(302) 252-9160
Website
enovis.com
Employees
7,802, Dec 31, 2025
Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
ENOV
Former tickers
CFX until Apr 8, 2022
Exchange
NYSE
IPO date
May 8, 2008
Shares outstanding
58M, Jul 31, 2026
Public float
$1.91B, Jul 4, 2025
Filer category
Large accelerated filer
Stock splits
1-for-3 reverse, May 10, 2022
SEC CIK
1420800
CUSIP
194014502
ISIN
US1940145022
FIGI
BBG000C5Z443
Share class FIGI
BBG001SC04J1
LEI
635400OP2DYYYMOIYL17
EIN
54-1887631

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Damien McDonaldChief Executive Officer, Director247,077
Matthew L. TrerotolaCEO, Director373,514
Oliver EngertChief Administrative Officer63,898
Phillip Benjamin (Ben) BerrySVP, Chief Financial Officer150,822
Laura Lee SingletonSVP, Chief HR Officer15,552
Patricia A. LangSVP, Chief HR Officer75,703
Bradley J. TandySVP and Chief Legal Officer65,641
John KlecknerPrincipal Accounting Officer25,884
Terry D. RossGROUP PRESIDENT, P&R68,477
Louis VogtGROUP PRESIDENT, RECON68,875
Angela S. LalorDirector34,997
Sharon L. WienbarDirector45,551
Christine OrtizDirector26,815
Rajiv VinnakotaDirector37,608
A. Clayton PerfallDirector56,672
Barbara W. BodemDirector24,201
Philip OkalaDirector24,201
Brady ShirleyDirector110,589
Liam KellyDirector28,950

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Peo1
$9.24M$6.13M$2.93M$41$79
FY2025
Peo2
$9.42M$1.47M$2.93M$41$79
FY2024
Peo
$12.45M$4.87M$2.78M$67$79
FY2024
Peo2
$12.45M$4.87M$2.78M$67$79
FY2023
Peo
$10.77M$11.81M$3.60M$85$75
FY2023
Peo2
$10.77M$11.81M$3.60M$85$75

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Damien McDonald
Chief Executive Officer
$634.62K$7.26M$812.75K$532.15K$9.24M–
Matthew L. Trerotola
Executive Advisor – former Chief Executive Officer
$857.46K$7.27M$988.22K$305.46K$9.42M-24%
Phillip “Ben” Berry
Chief Financial Officer
$604.92K$4.03M$464.00K$36.85K$5.14M+50%
Daniel A. Pryor
Former Executive Vice President, Strategy and Business Development
$614.92K$1.87M$457.31K$89.24K$3.03M-14%
Terry Ross
Group President, P&R
$514.92K$1.40M$388.62K$65.86K$2.37M–
Patricia Lang
Senior Vice President and Chief Human Resources Officer
$502.46K$1.15M$358.52K$67.86K$2.08M-10%
Louis Vogt
Group President Recon
$500.00K$1.17M$344.63K$22.50K$2.03M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 8, 2008
Offer price
$18.00
Securities offered
18,750,000
Gross proceeds
$337.50M
Exchange
NYSE
First trading day
May 8, 2008
First-day close
$63.00+250.0%
Lock-up ends (est.)
Nov 4, 2008

“Per Share Total Public offering price $18.00 $ 337,500,000 Underwriting discount $1.215 $22,781,250 Proceeds, before expenses, to Colfax Corporation $ 16.785 $ 151,731,902 Proceeds, before expenses, to the selling stockholders (1) $ 16.785 $ 162,986,848 (1) The selling stockholders are Mitchell P.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed approximately 7,802 persons, of whom approximately 2,107 were employed in the United States and approximately 5,695 were employed outside of the United States.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?